Rubitecan
- Generic Name
- Rubitecan
- Drug Type
- Small Molecule
- Chemical Formula
- C20H15N3O6
- CAS Number
- 91421-42-0
- Unique Ingredient Identifier
- H19C446XXB
- Indication
Investigated for use/treatment in pancreatic cancer, leukemia (unspecified), melanoma, ovarian cancer, and cancer/tumors (unspecified).
Aerosolized Liposomal Camptothecin in Patients With Metastatic or Recurrent Cancer of the Endometrium or the Lung
- Conditions
- Corpus UteriLung Cancer
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2010-01-07
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 24
- Registration Number
- NCT00277082
- Locations
- 🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States
Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)
- Conditions
- Corpus UteriEndometrial Cancer
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2010-01-07
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 39
- Registration Number
- NCT00249990
- Locations
- 🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States
Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2005-06-07
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT00113256
- Locations
- 🇺🇸
Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States
🇺🇸Medical Oncology, Baton Rouge, Louisiana, United States
🇺🇸N. Mississippi Hematology & Oncology Associates, Tupelo, Mississippi, United States
Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
- Conditions
- Tumors
- First Posted Date
- 2005-06-06
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT00113113
- Locations
- 🇺🇸
The Center for Cancer Care and Research, Saint Louis, Missouri, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Nitrocamptothecin in Treating Patients With Glioblastoma Multiforme
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2004-06-18
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 17
- Registration Number
- NCT00005826
- Locations
- 🇮🇹
Azienda Ospedaliera di Padova, Padua, Italy
🇫🇷Centre Eugene Marquis, Rennes, France
🇫🇷Institut Gustave Roussy, Villejuif, France
Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Registration Number
- NCT00005871
- Locations
- 🇺🇸
SuperGen, Incorporated, San Ramon, California, United States
Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2004-04-26
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Registration Number
- NCT00005870
- Locations
- 🇺🇸
SuperGen, Incorporated, San Ramon, California, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-04-13
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Registration Number
- NCT00005873
- Locations
- 🇺🇸
SuperGen, Incorporated, Dublin, California, United States
Nitrocamptothecin in Treating Patients With Metastatic Melanoma
- Conditions
- Melanoma (Skin)
- First Posted Date
- 2004-04-13
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Registration Number
- NCT00005875
- Locations
- 🇺🇸
SuperGen, Incorporated, Dublin, California, United States
Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas
- Conditions
- SarcomaSmall Intestine CancerGastrointestinal Stromal Tumor
- First Posted Date
- 2004-04-13
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Registration Number
- NCT00005874
- Locations
- 🇺🇸
SuperGen, Incorporated, Dublin, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.